未登录 分享 收藏
Integrative multi-omics profiling identifies infiltrative hepatocellular carcinoma as an immunotherapy-resistant subtype with distinct molecular features Lee, W.S.; Woo, S.; Lee, S.H.; Jo, G.H.; Kim, I.; Kim, H.; An, C.; Jung, S.; Kim, G.; Kang, H.; et al. 多组学整合分析鉴定出浸润性HCC为具有独特分子特征且对免疫治疗抵抗的亚型。韩国肝病杂志. 2025; 已接收. [Google Scholar] [CrossRef] Lee, Won Suk; Woo, Seonjeong; Lee, Sung Hwan; Jo, Gae Hoon; Kim, Ilhwan; Kim, Hyeyeong; An, Chansik; Jung, Sanghoon; Kim, Gwangil; Kang, Haeyoun; Kang, Beodeul; Kim, Jung Sun; Lim, Ho Yeong; Kang, Incheon; Yang, Hannah; Kong, So Jung; Son, Dahyeon; Shin, Dong Jun; Kwon, Woo Young; Lee, Da-Yeon; Lee, Ju-Seog; Park, Junho; Kim, Youngsoo; Hwang, Sohyun; Kim, Chan; Chon, Hong Jae 分享 收藏
分享 收藏
分享 收藏
分享 收藏
Development and Evaluation of a Next-Generation Medication Safety Support System Based on AI and Mixed Reality: A Study from South Korea 基于人工智能和混合现实的下一代用药安全支持系统的开发与评估：一项来自韩国的研究 Vieira, Nathan Lucien; Kim, Su Jin; Ahn, Sangah; Yoon, Ji Sim; Park, Sook Hyun; Hong, Jeong Hee; Kang, Min-Jeoung; Kim, Il; Son, Meong Hi; Cha, Won Chul; Yoo, Junsang 分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
Clinical Outcomes of Maintenance Durvalumab After Definitive Concurrent Chemoradiotherapy in Unresectable Locally Advanced Stage III NSCLC According to EGFR and ALK Status: Korean Cancer Study Group LU-22-18 根据EGFR和ALK状态，不可切除的局部晚期III期NSCLC在确定性同步放化疗后维持Durvalumab的临床结局: 韩国癌症研究小组LU-22-18 Choi, Dae-Ho; Kim, Miso; Kim, Young Saing; Park, Keon Uk; Cho, Jang Ho; Kim, Hongsik; Lee, Ki Hyeong; Ahn, Heejoon; Kim, Il-Hwan; Lee, Kyung-Hee; Lee, Gyeong-Won; Yi, Seong Yoon; Ahn, Beung chul; Lee, Min-Young; Jung, Hyun Ae; Park, Sehhoon; Sun, Jong-Mu; Ahn, Jin Seok; Lee, Se-Hoon; Ahn, Myung-Ju 分享 收藏
Interim analysis (IA) of SPADE: A prospective, real-world study of avelumab first-line maintenance (1LM) treatment in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) in the Asia-Pacific (APAC) region SPADE研究的期中分析（IA）：一项在亚太（APAC）地区对接受avelumab作为一线维持（1LM）治疗的局部晚期或转移性尿路上皮癌（la/mUC）患者（pts）进行的前瞻性、真实世界研究 Park, S. H.; Jo, J.; Kim, M.; Shin, S. J.; Kim, I-H.; Huang, Y-H.; Tsai, Y-C.; Oliveira, N.; Rajappa, S. J.; Wang, Y.; Hoffman, J.; Su, P. J. 分享 收藏
Real-world outcomes of long-term survivors of metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with liposomal irinotecan (nal-IRI) for the Asian cohort of NALLONG study NALLONG研究中接受脂质体伊立替康（nal-IRI）治疗的亚洲队列中，转移性胰腺导管腺癌（mPDAC）长期生存者的真实世界结局 Yoo, C.; Imaoka, H.; Okusaka, T.; Hong, J. Y.; Lee, C-K.; Kim, I.; van Laethem, J-L.; Macarulla Mercade, T.; Westphalen, C. B.; Prager, G.; Hedouin-Biville, F.; Chevallier, B.; Ueno, M. 分享 收藏
Second-Line Fluoropyrimidine-Based Chemotherapy in Advanced Biliary Tract Cancer: A Meta-analysis Based on Individual Patient-Level Data of Randomized Trials 二线以氟嘧啶为基础的化疗在晚期胆道癌中的应用：一项基于随机试验个体患者数据的Meta分析 Hyung, Jaewon; Kang, Minsu; Kim, Ilhwan; Kim, Kyu-pyo; Ryoo, Baek-Yeol; Cheon, Jaekyung; Ryu, Hyewon; Lee, Ji Sung; Kim, Ji-Won; Choi, In Sil; Park, Jin Hyun; Abou-Alfa, Ghassan K.; Kim, Jin Won; Yoo, Changhoon 分享 收藏
Efficacy and safety of liposomal irinotecan (nal-IRI) plus fluorouracil (5-FU) and leucovorin (LV) versus 5-FU/LV alone for advanced biliary tract cancer (BTC) after progression on gemcitabine-based therapy: A pooled analysis of the NIFTY and NALIRICC trials 脂质体伊立替康（nal-IRI）联合氟尿嘧啶（5-FU）和亚叶酸钙（LV）对比5-FU/LV单药治疗在吉西他滨为基础治疗后进展的晚期胆道癌（BTC）中的有效性和安全性：NIFTY和NALIRICC试验的合并分析 Yoo, C.; Saborowski, A.; Hyung, J.; Wenzel, P.; Kim, I.; Wege, H.; Kim, K-P; Folprecht, G.; Ryoo, B-Y; Schuett, P.; Cheon, J.; Goetze, T. O.; Ryu, H.; Lee, J. S.; Vogel, A. 分享 收藏
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population Durvalumab联合吉西他滨和顺铂治疗晚期胆道癌: 大量现实世界人口 Rimini, Margherita; Fornaro, Lorenzo; Rizzato, Mario Domenico; Antonuzzo, Lorenzo; Rossari, Federico; Satake, Tomoyuki; Vandeputte, Hanne; Vivaldi, Caterina; Pressiani, Tiziana; Lucchetti, Jessica; Kim, Jin Won; Abidoye, Oluseyi; Rapposelli, Ilario Giovanni; Tamberi, Stefano; Finkelmeier, Fabian; Giordano, Guido; Nichetti, Federico; Chon, Hong Jae; Braconi, Chiara; Pirrone, Chiara; Castet, Florian; Tamburini, Emiliano; Yoo, Changhoon; Parisi, Alessandro; Diana, Anna; Scartozzi, Mario; Prager, Gerald W.; Avallone, Antonio; Schirripa, Marta; Kim, Il Hwan; Perkhofer, Lukas; Oneda, Ester; Verrico, Monica; Adeva, Jorge; Chan, Stephen L.; Spinelli, Gian Paolo; Personeni, Nicola; Garajova, Ingrid; Rodriquenz, Maria Grazia; Leo, Silvana; Salani, Francesca; De Rosa, Antonio; Lavacchi, Daniele; Foti, Silvia; Ikeda, Masafumi; Dekervel, Jeroen; Niger, Monica; Balsano, Rita; Tonini, Giuseppe; Kang, Minsu; Bekaii-Saab, Tanios; Esposito, Luca; Boccaccino, Alessandra; Himmelsbach, Vera; Landriscina, Matteo; Djaballah, Selma Ahcene; Zanuso, Valentina; Masi, Gianluca; Lonardi, Sara; Rimassa, Lorenza; Casadei-Gardini, Andrea 分享 收藏
A prospective study for real-world data (RWD) of ramucirumab plus paclitaxel in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (KCSG ST21-06) Zang, D. Y.; Maeng, C. H.; Kim, J. Y.; Ryu, M. H.; Lee, K-W.; Jung, M.; Han, H. S.; Kim, B.; Oh, D-Y.; Kim, J. G.; Kim, I-H.; Sym, S. J.; Kim, J-J.; Choi, W.; Shin, S. H.; Kang, S. Y.; Song, E-K.; Im, H-S.; Cho, J. H.; Kim, S. T. 分享 收藏
Effect of NALIRIFOX in Asian patients (pts) with treatmentnaive metastatic pancreatic adenocarcinoma (mPAC): Results from the NAPOLI 3 trial Lee, W.; Kim, I-H.; Oh, S. C.; Lomma, C.; Macarulla Mercade, T.; Zervoudakis, A.; Vicuna, B.; Sampat, K.; Bullock, A.; Segelov, E.; Paulson, A. S.; Peguero, J.; Hassan, H.; Delaporte, F.; Martin Fernandez, L.; Causse-Amellal, N.; Melisi, D. 分享 收藏
分享 收藏
.png){kind=icon}
.png){kind=icon}
.png)
OAAI
.png){kind=icon}
分享.png){kind=icon}
收藏
.png)
ANNALS OF ONCOLOGY